News
-
AstraZeneca announced that the FDA has approved the company’s Breztri Aerosphere budesonide / glycopyrrolate / formoterol MDI for the treatment of asthma in patients aged 12 and older. The agency originally approved Breztri for the treatment of… Read more . . .
-
Inhaled drug developer Avalyn Pharma has announced the appointments of attorney Adam Golden as General Counsel and Head of Business Development and pharma sales and marketing veteran Frank Salisbury as Senior VP, Commercial. Golden was… Read more . . .
-
Cipla has received FDA approval of its ANDA for a generic version of Ventolin HFA albuterol MDI for the treatment of asthma, the company announced. GSK’s NDA Ventolin HFA was approved by the agency in… Read more . . .
-
Rocket Science Health announced that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 12,569,658, titled “Dual Nozzles For Insertion Into Paired Body Orifices (e.g., Nasal Passages, Etc.)” covering the company’s intranasal… Read more . . .
-
Vistagen announced that it has received a “study may proceed” letter from the FDA in response to the company’s IND for a Phase 2 trial of refisolone nasal spray for the treatment of hot flashes caused… Read more . . .
-
Savara has announced that the FDA is giving itself extra time to review the company’s BLA for molgramostim inhalation solution for the treatment of autoimmune pulmonary alveolar proteinosis, setting November 22, 2026 as the new… Read more . . .
-
ARS Pharmaceuticals and ALK announced that Canadian regulators have approved a 2 mg dose of neffy epinephrine nasal spray for the treatment of anaphylaxis in adults and children who weigh at least 30 kg. The… Read more . . .
-
Amneal Pharmaceuticals has announced the launch of a generic beclomethasone MDI and a generic albuterol MDI in the US, noting that these are its first metered dose inhalers in the US market. The company had… Read more . . .
-
DPI developer Iconovo has announced that interim CEO Anders Månsson will be the company’s permanent CEO. Månsson was named interim CEO at the end of October 2025, afterJohan Wäborg announced that he would step down. He had… Read more . . .
-
Oragenics said that it has initiated a Phase 2a trial of ONP-002, a dry powder intranasal neurosteroid, for the treatment of mild traumatic brain injury in Australia after receiving approval from the Human Research Ethics… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK